Drugs / ASP9521
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01352208 | Mar 2011 → Sep 2012 | castration-resistant prostate carcinoma | Astellas Pharma Inc | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP9521 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01352208 ↗ |
| Action | Inhibit | “ASP9521 is a first-in-class orally available inhibitor of the enzyme 17 β-hydroxysteroid dehydrogenase type 5” PMID 24771350 ↗ Apr 2014 |
| Modality | Small molecule | — CHEMBL4513510 ↗ |
| Route | Oral | “Eligible patients received ASP9521 orally for 12 weeks” PMID 24771350 ↗ Apr 2014 |